{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:35:45Z","timestamp":1780929345972,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00280-018-3713-6","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T03:47:38Z","timestamp":1540784858000},"page":"115-122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?"],"prefix":"10.1007","volume":"83","author":[{"given":"Osman","family":"K\u00f6stek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet Bekir","family":"Hac\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Sakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tar\u0131k","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Sar\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Ozkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Araz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysun Fatma","family":"Do\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naz\u0131m Can","family":"Demircan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sernaz","family":"Uzuno\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130rfan","family":"\u00c7i\u00e7in","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fclent","family":"Erdo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"key":"3713_CR1","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1200\/JCO.2015.63.0558","volume":"34","author":"MA Shah","year":"2016","unstructured":"Shah MA, Renfro LA, Allegra CJ et al (2016) Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the Adjuvant Colon Cancer End Points (ACCENT) database. J Clin Oncol 34:843\u2013853","journal-title":"J Clin Oncol"},{"key":"3713_CR2","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065\u20131075","journal-title":"Lancet Oncol"},{"key":"3713_CR3","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook AP, Niedzwiecki D, Lenz HJ et al (2017) Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317:2392\u20132401","journal-title":"JAMA"},{"key":"3713_CR4","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"5","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 5:1539\u20131544","journal-title":"J Clin Oncol"},{"issue":"9863","key":"3713_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303\u2013312","journal-title":"Lancet"},{"key":"3713_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","volume":"16","author":"J Li","year":"2015","unstructured":"Li J, Qin S, Xu R et al (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16:619\u2013629","journal-title":"Lancet Oncol"},{"key":"3713_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"issue":"4","key":"3713_CR8","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/annonc\/mdy038","volume":"29","author":"D Arnold","year":"2018","unstructured":"Arnold D, Prager GW, Quintela A et al (2018) Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. Ann Oncol 29(4):835\u2013856","journal-title":"Ann Oncol"},{"issue":"3","key":"3713_CR9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.clcc.2018.04.002","volume":"17","author":"AK Patel","year":"2018","unstructured":"Patel AK, Duh MS, Barghout V et al (2018) Real-world treatment patterns among patients with colorectal cancer treated with trifluridine\/tipiracil and regorafenib. Clin Colorectal Cancer 17(3):531\u2013539","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"3713_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s10147-015-0911-7","volume":"21","author":"C Matsuda","year":"2016","unstructured":"Matsuda C, Honda M, Tanaka C et al (2016) Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study). Int J Clin Oncol 21(3):566\u2013572","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"3713_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/01.cad.0000127144.73043.57","volume":"15","author":"JT Hartmann","year":"2004","unstructured":"Hartmann JT, Oechsle K, Jager E et al (2004) Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. Anticancer Drugs 15(5):473\u2013477","journal-title":"Anticancer Drugs"},{"key":"3713_CR12","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.2147\/DDDT.S85567","volume":"9","author":"M Suenaga","year":"2015","unstructured":"Suenaga M, Mizunuma N, Matsusaka S et al (2015) Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: rE-OPEN study. Drug Des Devel Ther 9:3099\u20133108","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"3713_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3816\/CCC.2006.n.013","volume":"5","author":"V Gebbia","year":"2006","unstructured":"Gebbia V, Del Prete S, Borsellino N et al (2006) Efficacy and safety of cetuximab\/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. Clin Colorectal Cancer 5(6):422\u2013428","journal-title":"Clin Colorectal Cancer"},{"key":"3713_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/1471-2407-9-347","volume":"9","author":"A Lievre","year":"2009","unstructured":"Lievre A, Samalin E, Mitry E et al (2009) Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer 9:347","journal-title":"BMC Cancer"},{"issue":"3","key":"3713_CR15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000361031","volume":"87","author":"M Chaix","year":"2014","unstructured":"Chaix M, Vincent J, Lorgis V, Ghiringhelli F (2014) FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer. Oncology 87(3):148\u2013158","journal-title":"Oncology"},{"issue":"2","key":"3713_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3109\/0284186X.2011.614637","volume":"51","author":"FO Larsen","year":"2012","unstructured":"Larsen FO, Boisen MK, Fromm AL, Jensen BV (2012) Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer. Acta Oncol 51(2):231\u2013233","journal-title":"Acta Oncol"},{"issue":"5","key":"3713_CR17","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12094-014-1243-1","volume":"17","author":"P Jime\u00b4nez-Fonseca","year":"2015","unstructured":"Jime\u00b4nez-Fonseca P, Solis MP, Garrido M et al (2015) Gemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer. Clin Transl Oncol 17(5):384\u2013392","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"3713_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000446372","volume":"91","author":"M Yoshida","year":"2016","unstructured":"Yoshida M, Takagane A, Miyake Y et al (2016) A phase II study of third-line combination chemotherapy with bevacizumab plus S-1 for metastatic colorectal cancer with mutated KRAS (SAVIOR study). Oncology 91(1):24\u201330","journal-title":"Oncology"},{"issue":"46","key":"3713_CR19","doi-asserted-by":"publisher","first-page":"6231","DOI":"10.3748\/wjg.v13.i46.6231","volume":"13","author":"HC Kwon","year":"2007","unstructured":"Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ (2007) Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 13(46):6231\u20136235","journal-title":"World J Gastroenterol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3713-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3713-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3713-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T20:15:37Z","timestamp":1572293737000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3713-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,29]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["3713"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3713-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,29]]},"assertion":[{"value":"6 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}